$Novavax(NVAX)$Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India
1. First authorization of Novavax' COVID-19 vaccine in adolescent population received
2. Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India
3. Authorization highlights immunogenicity and reassuring safety profile of Covovax in Phase 2/3 study of Indian adolescents aged ≥12 to <18 and data from an ongoing Phase 3 pediatric expansion trial of NVX-CoV2373 in adolescents aged ≥12 to <18 in the U.S.
Extracted from:
https://ir.novavax.com/2022-03-22-Novavax-and-Serum-Institute-of-India-Announce-First-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-in-Adolescents-12-to-18-in-India?sf162469358=1
Comments